Office Of Alternative Medicine Gets Unexpected Boost

A proposal to elevate the National Institutes of Health's Office of Alternative Medicine (OAM) into an institute fell short during the appropriations process, but a 60 percent increase in funding represents a victory of sorts for the office. The $8-million boost proposed by a conference committee would raise OAM's current $12-million budget to $20 million for FY1998. The conference committee's decision was a surprise considering earlier requests. The House and the Clinton administration both so

Written byPaul Smaglik
| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share

A proposal to elevate the National Institutes of Health's Office of Alternative Medicine (OAM) into an institute fell short during the appropriations process, but a 60 percent increase in funding represents a victory of sorts for the office. The $8-million boost proposed by a conference committee would raise OAM's current $12-million budget to $20 million for FY1998.

The conference committee's decision was a surprise considering earlier requests. The House and the Clinton administration both sought cuts in the office's funding, down to $7.5 million for 1998; the Senate requested a slight funding increase, to $13 million. If OAM had been elevated to an NIH institute, it could have received a $200-million annual budget.

The OAM's status sparked a debate during an October 9 Senate hearing over who should have granting authority for studies of unconventional therapies-skeptical scientists or alternative medicine proponents. Critics say that therapies investigated by OAM should undergo ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies